News& Press Releases

Åsa Johansson, CEO "We are thrilled to announce a significant leadership transition at Offspring Biosciences, marking an exciting new chapter for our company. Effective January 1st, 2025, Åsa Johansson will be stepping into the role of Chief Executive Officer (CEO), succeeding Anders Dahlstrand in this position.” T his change in leadership comes as Anders Dahlstrand, our former CEO, refocuses his role to leverage his deep expertise in business and science development. This st

We are happy to welcome Åsa Johansson to Offspring Biosciences as our new Head of Operations. Åsa will have the responsibility for overseeing HR, Finance, and Operations.  Åsa has over ten years of experience in leading positions. She has navigated roles in both the public and private sectors, along with academia. Her expertise spans over more than two decades within the field of clinical microbiology and medical biochemistry. Skilled in an array of laboratory techniques incl

Unlocking the combined value of Offspring’s innovative pre-clinical solutions with Flagship’s clinical trial data-driven assay solutions Broomfield, CO, USA and Södertälje, Sweden – January 24, 2024 Flagship Biosciences, a leader in spatial biology and biomarker analytics services, and Offspring Biosciences, an innovator in pre-clinical biomarker assay solutions, today announced a strategic partnership that aims to further advance precision drug development with a complete bi

Join us in welcoming Anders Nordström to the Offspring Biosciences family as the new Chairman of the Board.   With a rich background in the Life Science industry, Anders has served and serves as Chairman or Board member for prominent companies such as Pelago Bioscience, Vanadis Diagnostics, Cartana, Halo Genomics, Moleculent, , Genagon Therapeutics, Fenomark Diagnostics and Epigenica.   His expertise extends to pivotal roles, including as Senior Advisor for Business Developme

In a recently published study by a research team from MedImmune led by Dr. Arun Sharma, novel data was presented which shows that in vivo treatment with a combination of the neurotrophic factor neuturin (NRTN) and liraglutide in hyperglycemic ZDF rats synergistically improved glycemic control and enhanced metabolic parameters as compared to liraglutide alone, highlighting the potential of novel combinatorial approaches to prevent or reverse diabetes progression Offspring are